financetom
Business
financetom
/
Business
/
Snowflake Likely to Beat First-Quarter Revenue Views, RBC Say
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Snowflake Likely to Beat First-Quarter Revenue Views, RBC Say
May 20, 2024 12:12 PM

02:49 PM EDT, 05/20/2024 (MT Newswires) -- Snowflake (SNOW) is tracking toward a modest fiscal first-quarter revenue beat and positive guidance revisions amid potential product sales upside, RBC Capital Markets said in a note emailed Monday.

The brokerage said markets are assuming 2% to 3% upside to the first-quarter consensus for total revenue of $787 million and product revenue of $744 million. They both imply year-over-year growth of 26%. Shares of Snowflake were up 1.5% in afternoon trade.

The cloud-based data analytics platform topped product expectations by an average of 2.9% over the last four quarters, according to RBC's analysis. A 2.5% beat in the May 22 report would imply product revenue closer to $762 million, a year-over-year gain of 29%, according to RBC.

RBC is modeling for first-quarter total revenue of $784.5 million and adjusted earnings per share of $0.15, compared with the $0.17 average analyst estimate on Capital IQ.

"We see a better setup this quarter and look for slight upside to estimates and guidance," Matthew Hedberg, RBC's head of global technology, internet, media and telecommunications research, said.

The brokerage reiterated an outperform rating on the stock but lowered its price target to $220 from $246 on "peer group multiple compression." Since the fourth-quarter earnings report, the stock has dropped 29%, compared with a 5% gain for the S&P 500, according to the note.

The target price is based on an 18-times multiple to RBC's 2025 calendar-year revenue estimate.

For the remainder of fiscal 2025, RBC believes estimates can move higher due in part to the potential for artificial intelligence products to contribute to results this year, accelerating consumption trends, and embedded conservatism in the guidance due to February's chief executive change.

While management initially guided for 22% revenue growth, RBC sees a "reasonable path" to 27%-plus growth.

Price: 164.40, Change: +2.54, Percent Change: +1.57

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs'
Oct 16, 2025
Shares of Eli Lilly And Co ( LLY ) and Novo Nordisk A/S ( NVO ) are moving lower in Thursday’s after-hours session after President Donald Trump indicated that weight-loss drugs are going to come down in price. • LLY stock is showing weakness. Get the complete picture here. What To Know: In a press conference from the White House...
WaFd Fiscal Q4 Non-GAAP Earnings Rise, Revenue Falls
WaFd Fiscal Q4 Non-GAAP Earnings Rise, Revenue Falls
Oct 16, 2025
05:25 PM EDT, 10/16/2025 (MT Newswires) -- WaFd ( WAFD ) reported fiscal Q4 non-GAAP earnings late Thursday of $0.72 per diluted share, up from $0.68 a year earlier. Four analysts polled by FactSet expected $0.77. Revenue for the quarter ended Sept. 30, expressed as the sum of net interest income and total noninterest income, was $188.3 million, down from...
Uipath Insider Sold Shares Worth $2,112,412, According to a Recent SEC Filing
Uipath Insider Sold Shares Worth $2,112,412, According to a Recent SEC Filing
Oct 16, 2025
05:27 PM EDT, 10/16/2025 (MT Newswires) -- Daniel Dines, 10% Owner, Director, CEO and Chairman, on October 16, 2025, sold 122,734 shares in Uipath ( PATH ) for $2,112,412. Following the Form 4 filing with the SEC, Dines has control over a total of 30,158,585 Class A common shares of the company, with 29,918,585 shares held directly and 240,000 controlled...
Trump says price of Ozempic will be lowered
Trump says price of Ozempic will be lowered
Oct 16, 2025
WASHINGTON (Reuters) -U.S. President Donald Trump said on Thursday that the price of Novo Nordisk's best-selling weight-loss drug would be lowered and that negotiations over price changes would be swift. Trump made the comments during a White House event on fertility treatments and drug pricing. He was asked by reporters to identify the name of a drug that he earlier...
Copyright 2023-2026 - www.financetom.com All Rights Reserved